10-K: CN Healthy Food Tech: Growth, Nasdaq Halt, China Regulatory Risks

CN Healthy Food Tech Group Corp. reports significant revenue and net income growth in 2025, yet faces a Nasdaq trading halt, defaulted promissory notes, and material weaknesses in internal controls.

Summary

• CN Healthy Food Tech Group Corp. is a holding company focused on R&D, production, and sales of high-end bio-health foods, integrating AI-powered biotechnology and traditional Chinese medicine principles.
• The company's operations are primarily in China, with a north-south layout across Daqing, Harbin, and Zhuhai, and plans for overseas expansion.
• Key products include Cordyceps Peptide Selenium Powder, Baofei Granule Extract Plant Beverage, Yanxu Peptide Selenium Premium Powder, and Panax Ginseng Peptide Selenium Concentrate Powder.
• Revenue for the year ended December 31, 2025, increased by 144.6% to $27.8 million, up from $11.3 million in 2024.
• Net income for 2025 grew by 110.5% to $8.4 million, compared to $4.0 million in 2024.
• A Nasdaq trading halt has been in effect since October 1, 2025, due to an uncompleted review process by the China Securities Regulatory Commission (CSRC) regarding the company's U.S. listing.
• Three interest-free promissory notes, totaling $3,473,190, are in default as of December 31, 2025, with the company negotiating extensions.
• The company identified material weaknesses in its internal controls over financial reporting, including insufficient GAAP-familiar personnel, lack of oversight committees, and inadequate segregation of duties.
• An in-house production base commenced operations in October 2025, contributing 13% to annual revenue and reducing reliance on external suppliers.
• The company maintains a strong cash position of $33.01 million as of December 31, 2025, which management believes is sufficient to cover debts and operational needs for at least the next 12 months.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with strong financial growth overshadowed by significant regulatory and operational challenges, particularly the Nasdaq trading halt, uncompleted CSRC review, and defaulted debt, which introduce substantial uncertainty and risk.

Positives

• Total revenue increased significantly by 144.6% to $27.8 million for the year ended December 31, 2025, driven by strategic promotional campaigns and new product launches.
• Net income grew by 110.5% to $8.4 million in 2025, demonstrating strong profitability.
• Gross profit increased by 144.1% to $18.4 million in 2025, reflecting efficient cost management relative to revenue growth.
• Operating income rose by 112.5% to $11.8 million in 2025, indicating improved operational efficiency.
• The company's own production base commenced operations in October 2025, contributing 13% to annual revenue and strengthening control over product quality, cost, and supply chain efficiency.
• A robust R&D system is in place, with collaborations with authoritative domestic research institutions and a focus on AI-powered biotechnology and traditional Chinese medicine.
• The company holds significant intellectual property, including 13 registered patents, 85 trademarks, and 6 copyrights in mainland China as of December 31, 2025.
• Management asserts no material doubts regarding the company's ability to continue as a going concern, citing sufficient cash on hand ($33.01 million) to cover all debts and ongoing negotiations for defaulted notes.

Negatives

• Nasdaq trading of the company's common stock and warrants has been halted since October 1, 2025, due to an uncompleted review process by the China Securities Regulatory Commission (CSRC) for its U.S. listing.
• Three interest-free promissory notes, totaling $3,473,190, are in default as of December 31, 2025, requiring ongoing negotiations for maturity date extensions.
• Operating activities used $9.0 million in cash in 2025, a significant reversal from providing $42.1 million in 2024, primarily due to a $21.2 million decrease in advances from customers.
• Material weaknesses were identified in internal controls over financial reporting, including insufficient personnel familiar with U.S. GAAP, absence of oversight committees, and inadequate staffing for segregation of duties.
• Total operating expenses increased by 231.6% to $6.6 million in 2025, partly due to costs associated with the Business Combination and becoming a public company.
• The company faces significant risks related to complex and evolving Chinese laws and regulations, including those concerning regulatory approvals for overseas issuances, antitrust actions, and data privacy.
• Uncertainty remains regarding the timely completion of the CSRC filing for the corporate merger, which could lead to sanctions or restrictions on operations.

Risks

• The Nasdaq trading halt, in effect since October 1, 2025, due to an uncompleted CSRC review, may lead to delisting, limited market quotes, reduced trading activity, and impaired ability to raise future capital.
• Delisting from Nasdaq could result in shareholder lawsuits, negative impact on stock price, and reduced liquidity, with no guarantee of relisting or market stabilization.
• Failure to obtain or delays in obtaining CSRC approval for the U.S. listing, or revocation of such approval, could lead to sanctions, fines, restrictions on dividend distribution, and significant adverse impacts on business and stock value.
• The company's operations in China are subject to significant influence and intervention from the Chinese government, including legislative and regulatory changes in securities, data protection, cybersecurity, taxation, and foreign investment.
• Limited operational history under the current business structure introduces uncertainty in forecasting future revenues, budgeting expenditures, and assessing the ability to meet market demands and expand production capacity.
• Uncertainties in the interpretation and enforcement of rapidly evolving Chinese laws and regulations, some based on undisclosed government policies, could adversely affect operations.
• Increased scrutiny and additional disclosure requirements from the U.S. SEC for companies with significant China operations could raise compliance costs and hinder future securities offerings.
• New or stricter government policies in China affecting specific industries, such as corporate social responsibility or environmental protection, may lead to higher compliance costs or operational restrictions.
• Vulnerability to cyberattacks, data breaches, and non-compliance with increasingly stringent data protection and cybersecurity laws (e.g., PIPL, Data Security Law) could result in substantial fines, operational restrictions, and reputational damage.
• Exchange rate fluctuations of the RMB against the U.S. dollar, influenced by Chinese government policies and economic conditions, may lead to foreign exchange conversion losses and adversely affect the value of shares and foreign currency dividends.
• Risk of intellectual property infringement claims from third parties, which could entail substantial defense costs and disrupt business operations.
• Inability to prevent unauthorized use of the company's own intellectual property (patents, trademarks, trade secrets) due to challenges, invalidation, or the evolving nature of IP protection in China.
• The exercise of 9,357,000 outstanding warrants at $11.50 per share could result in diluted shareholder equity and increased share availability for resale in the open market.
• The market prices of common shares and warrants may experience significant fluctuations due to various factors, including financial performance, regulatory changes, litigation, and broader economic conditions.
• Reliance on a few key suppliers for inventory, despite diversification efforts, poses a risk of supply chain disruptions if a supplier encounters production issues or increases prices.
• Restrictions imposed by the PRC government on the conversion and remittance of RMB out of mainland China may limit the ability to pay dividends to overseas entities and U.S. investors.
• Classification as a PRC resident enterprise for tax purposes could subject the company to a 25% enterprise income tax rate on its worldwide income, materially reducing net income.

Future Outlook

The company aims to become a global leader in high-end health food innovation by leveraging AI technology and biotech innovation. It plans comprehensive upgrades to its production bases, including automated lines, precision testing equipment, and intelligent warehouse management systems, to significantly increase core product output capacity. Office facilities will be modernized with new R&D laboratories and remote collaboration systems. The company also intends to establish a chain network of Traditional Chinese Medicine (TCM) health centers starting in 2025 and develop advanced digital tools for marketing and customer service. The self-production ratio for core products is expected to continue increasing.

Management Comments

• Our corporate vision is to create a healthy world through AI technology and biotechnology.
• The product advocates a green, healthy, international, and popular consumption concept, which is widely welcomed by the market.
• Management has assessed that there are no material doubts regarding the company's ability to continue as a going concern.
• Management will consider implementing remedial measures designed to address the aforementioned material weakness and strengthen the company's internal controls over financial reporting.

Industry Context

StockSavvy.ai notes that CN Healthy Food Tech operates in the highly competitive and innovation-driven biotechnology high-end health food sector in China. The company's strategy of integrating AI-powered biotechnology with traditional Chinese medicine principles positions it to capitalize on the growing consumer demand for safe, high-quality nutritional products, aligning with broader trends of health awareness and consumption upgrades. Its north-south operational layout and expansion into overseas markets indicate a strategic effort to gain market share against established domestic and international players. The use of AI digital human technology for live-streaming sales is a modern approach to consumer engagement, reflecting industry shifts towards digital marketing.

Comparison to Industry Standards

• The company aims to capture over 15% market share in the natural grain and processed health food markets in China, an ambitious target in a competitive landscape with established domestic and international players.
• Its R&D collaboration with Professor Xu Liran, an expert with State Council Special Government Allowance and multiple national research projects, suggests a commitment to high-level scientific innovation, potentially comparable to leading biotech firms in the health sector.
• The establishment of its own 18,000 square meter production base in Taikang Industrial Park, Daqing City, with plans for comprehensive upgrades to automated lines and intelligent systems, indicates an investment in infrastructure that aligns with modern manufacturing best practices in the health food sector.
• The company's focus on 'green ecological products' and the 'non-GMO agricultural sector' aligns with global consumer trends towards sustainable and natural products, similar to the positioning of organic food brands or companies like Beyond Meat in the plant-based sector, though specific product-level comparisons are not provided.
• The adoption of AI-powered marketing systems and digital employee anchors for live-streaming sales reflects an embrace of advanced e-commerce strategies, positioning the company alongside leading consumer goods firms in the rapidly evolving Chinese digital market.

Corporate Governance

Legal Proceedings

• The company is not currently involved in, nor aware of any threats of, legal or administrative proceedings that would have a material adverse effect on its business, financial condition, cash flow, or operating results.
• As the business grows, the company may become involved in ordinary course legal or administrative proceedings, including those related to intellectual property infringement, third-party license violations, contract disputes, and labor or employment claims.
• Should Nasdaq ultimately decide to delist the company's securities, it may face shareholder lawsuits, which would have a significant adverse impact on operations, divert management attention, and impair business performance, profitability, and reputation.

Related Party Transactions

• On May 30, 2024, the stockholder of Rosy Sea contributed a building with a fair value of $4,332,228 and a land use right with a fair value of $2,838,603 (as of December 31, 2025) to the company.
• As part of the Business Combination, $2,000,000 in compensation was owed to the Sponsor, Bengochea SPAC Sponsors I LLC. Of this, $1,000,000 was included in accrued expenses, $900,000 as part of a promissory note, and $100,000 was paid at closing.
• As of December 31, 2025, $1,000,000 of unpaid compensation was owed to the Sponsor, and $454,690 remained outstanding under promissory notes with the Sponsor, which are currently in default.
• Mr. Jiang Zhenjun, a group shareholder, paid $1,715,250 in acquisition-related fees on behalf of Iron Horse.
• Mr. Jiang Zhenjun also paid various fees on behalf of CFI and CFI HK, including 2024 annual audit fees ($78,000), U.S. agent fees ($3,825), 2025 annual filing fees (HK$16,280), and name change fees (RMB 7,755 for CFI, HKD 4,500 and RMB 2,068 for CFI HK).

Stakeholder Impact

• Shareholders face significant risks due to the Nasdaq trading halt, potential delisting, and dilution from outstanding warrants. The default on promissory notes also introduces financial uncertainty that could impact shareholder value.
• Employees may be affected by the identified material weaknesses in internal controls, but also benefit from the company's growth and investment in R&D and production facilities.
• Customers are targeted with high-quality, natural, and healthy products, with enhanced R&D and quality control aiming to increase satisfaction and loyalty. AI-powered marketing and customer service systems are designed to improve engagement and service delivery.
• Suppliers have formalized relationships through OEM agreements and undergo rigorous evaluations. However, reliance on a few key suppliers still presents a risk of supply chain disruptions.
• Creditors, particularly those holding the three defaulted promissory notes, face immediate risk due to non-payment, although the company is negotiating extensions and maintains sufficient cash reserves to cover these obligations.

Next Steps

• Await further notification from Nasdaq regarding the trading halt and clarification of matters with the China Securities Regulatory Commission (CSRC).
• Complete the filing procedures related to the corporate merger with the CSRC.
• Negotiate with creditors to extend the maturity dates of the defaulted promissory notes.
• Implement comprehensive upgrades at existing production bases, including automated production lines, precision testing equipment, and intelligent warehouse management systems.
• Modernize office facilities with newly established R&D laboratories, sample display areas, and remote collaboration systems.
• Establish a chain network of Traditional Chinese Medicine (TCM) health centers, with initiatives starting from 2025.
• Develop advanced digital tools such as AI-powered marketing solutions and an AI-driven customer service system to optimize distribution efficiency and enhance satisfaction.
• Formulate and implement insider trading policies and procedures by 2026.
• Address material weaknesses in internal controls over financial reporting by seeking additional GAAP/SEC accounting professionals, engaging external consultants, enhancing review procedures, and strengthening documentation of key control measures.

Key Dates

Recommendation

The company exhibits strong revenue and net income growth, indicating a robust underlying business in the high-end health food sector. However, the ongoing Nasdaq trading halt due to an uncompleted CSRC review, the default on significant promissory notes, and identified material weaknesses in internal controls over financial reporting introduce substantial regulatory, financial, and operational uncertainties. These issues create significant downside risk for investors, making the stock highly speculative until these critical matters are resolved. The potential for delisting and the challenges in China's evolving regulatory environment further compound the risks, outweighing the positive financial performance in the short to medium term.

Keywords

Health Food, Biotechnology, AI Technology, China Market, SEC Filing, Nasdaq Halt, CSRC Review, Corporate Governance, Risk Factors, Financial Performance, UCFI, Health Products, Nutritional Products, Supply Chain, Intellectual Property, Internal Controls, Promissory Notes, Delisting Risk, China Regulation, E-commerce, Live-stream Sales